Skip to main content
SpringerLink
Log in

Travellers’ Diarrhoea: Contemporary Approaches to Therapy and Prevention

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Travellers’ diarrhoea remains a major public health problem, contributing to significant morbidity and disability. Because bacterial enteropathogens cause a majority of this form of diarrhoea, antibacterial drugs are effective when used in chemoprophylaxis or for empirical treatment.

A review of the MEDLINE listings for travellers’ diarrhoea for the past 4 years was conducted; a library of >1000 scientific articles on the topic was also considered in developing this review.

Persons who travel from industrialised countries to developing countries of the tropical and semitropical world are the individuals who experience travellers’ diarrhoea. While diarrhoea occurs with reduced frequency among persons travelling to low-risk areas from other low- or other high-risk areas, and there remain areas of intermediate risk, this review looks primarily at the illness occurring in persons from industrialised regions visiting high-risk regions of Latin America, Africa and Southern Asia.

The material reviewed deals with the high frequency of acquiring diarrhoea during international travel to high-risk areas, seen in approximately 40%, and the expected bacterial causes of illness, of which diarrhoeagenic Escherichia coli is the most important. The host risk factors associated with increased susceptibility to diarrhoea include young age, lack of previous travel to high-risk regions in the past 6 months, indiscriminate food and beverage selection patterns, and host genetics.

It appears feasible to decrease the rate of illness among the travelling public by careful food and beverage selection or through chemoprophylaxis with nonabsorbed rifaximin. Chemoprophylaxis with rifaximin should help to reduce the occurrence of travellers’ diarrhoea and hopefully prevent post-diarrhoea complications, including irritable bowel syndrome. Early empirical therapy with antibacterial drugs, including rifaximin, a fluoroquinolone or azithromycin, will decrease the duration of illness and return travellers more quickly to their planned activities.

With collaboration between local governments and public health researchers, it may be possible to improve hygiene in areas to be visited, which may translate into reduced rates of illness. More liberal use of rifaximin prophylaxis is likely to reduce the occurrence of illness and complications of disease. Vaccines and immunoprophylactic products may be beneficial for prevention of a subset of individuals otherwise developing diarrhoea.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. DuPont HL, Ericsson CD. Prevention and treatment of traveler’s diarrhea. N Engl J Med 1993; 328(25): 1821–7

    Article  PubMed  CAS  Google Scholar 

  2. Steffen R. Epidemiologic studies of travelers’ diarrhea, severe gastrointestinal infections, and cholera. Rev Infect Dis 1986; 8 Suppl. 2: S122–30

    Article  PubMed  Google Scholar 

  3. Kean BH. The diarrhea of travelers to Mexico: summary of five-year study. Ann Intern Med 1963; 59: 605–14

    PubMed  CAS  Google Scholar 

  4. Kean BH, Schaffner W, Brennan RW. The diarrhea of travelers: V. Prophylaxis with phthalylsulfathiazole and neomycin sulphate. JAMA 1962; 180: 367–71

    CAS  Google Scholar 

  5. Kean BH, Waters S. The diarrhea of travelers: I. Incidence in travelers returning to the United States from Mexico. AMA Arch Ind Health 1958; 18(2): 148–50

    CAS  Google Scholar 

  6. Kean BH, Waters SR. The diarrhea of travelers: III. Drug prophylaxis in Mexico. N Engl J Med 1959; 261(2): 71–4

    CAS  Google Scholar 

  7. Owen JR. Diarrhoea at the Olympics. BMJ 1968; 4(631): 645

    Article  PubMed  CAS  Google Scholar 

  8. Adachi JA, Mathewson JJ, Jiang ZD, et al. Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas. Ann Intern Med 2002; 136(12): 884–7

    PubMed  Google Scholar 

  9. Tjoa WS, DuPont HL, Sullivan P, et al. Location of food consumption and travelers’ diarrhea. Am J Epidemiol 1977; 106(1): 61–6

    PubMed  CAS  Google Scholar 

  10. Wood LV, Ferguson LE, Hogan P, et al. Incidence of bacterial enteropathogens in foods from Mexico. Appl Environ Microbiol 1983; 46(2): 328–32

    PubMed  CAS  Google Scholar 

  11. Deetz T, Smith EM, et al. Occurrence of rota- and enteroviruses in drinking and environmental water in a developing nation. Water Res 1984; 18: 567–71

    Article  Google Scholar 

  12. Keswick BH, Gerba CP, DuPont HL, et al. Detection of enteric viruses in treated drinking water. Appl Environ Microbiol 1984; 47(6): 1290–4

    PubMed  CAS  Google Scholar 

  13. Bandres JC, Mathewson JJ, DuPont HL. Heat susceptibility of bacterial enteropathogens: implications for the prevention of travelers’ diarrhea. Arch Intern Med 1988; 148(10): 2261–3

    Article  PubMed  CAS  Google Scholar 

  14. Cash RA, Music SI, Libonati JP, et al. Response of man to infection with Vibrio cholerae: I. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis 1974; 129(1): 45–52

    CAS  Google Scholar 

  15. DuPont HL, Formal SB, Hornick RB, et al. Pathogenesis of Escherichia coli diarrhea. N Engl J Med 1971; 285(1): 1–9

    Article  PubMed  CAS  Google Scholar 

  16. Steffen R, van der Linde F, Gyr K, et al. Epidemiology of diarrhea in travelers. JAMA 1983; 249(9): 1176–80

    Article  PubMed  CAS  Google Scholar 

  17. Kozicki M, Steffen R, Schar M. ‘Boil it, cook it, peel it or forget it’: does this rule prevent travellers’ diarrhoea? Int J Epidemiol 1985; 14(1): 169–72

    Article  PubMed  CAS  Google Scholar 

  18. Paredes P, Campbell-Forrester S, Mathewson JJ, et al. Etiology of travelers’ diarrhea on a Caribbean island. J Travel Med 2000; 7(1): 15–8

    Article  PubMed  CAS  Google Scholar 

  19. Chaudhuri A, De S. Cholera and blood-groups. Lancet 1977; II(8034): 404

    Article  Google Scholar 

  20. Clemens JD, Sack DA, Harris JR, et al. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J Infect Dis 1989; 159(4): 770–3

    Article  PubMed  CAS  Google Scholar 

  21. Glass RI, Holmgren J, Haley CE, et al. Predisposition for cholera of individuals with O blood group: possible evolutionary significance. Am J Epidemiol 1985; 121(6): 791–6

    PubMed  CAS  Google Scholar 

  22. Huang P, Farkas T, Marionneau S, et al. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J Infect Dis 2003; 188(1): 19–31

    Article  PubMed  CAS  Google Scholar 

  23. Hutson AM, Atmar RL, Graham DY, et al. Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis 2002; 185(9): 1335–7

    Article  PubMed  Google Scholar 

  24. Greenberg DE, Jiang ZD, Steffen R, et al. Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli pathogenicity. J Infect Dis 2002; 185(7): 944–9

    Article  PubMed  Google Scholar 

  25. Jiang ZD, Okhuysen PC, Guo DC, et al. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis 2003; 188(4): 506–11

    Article  PubMed  CAS  Google Scholar 

  26. Bulmer E. A survey of tropical diseases as seen in the Middle East. Trans R Soc Trop Med Hyg 1944; 37: 225–42

    Article  Google Scholar 

  27. Higgins AR. Observations on the health of United States personnel living in Cairo, Egypt. Am J Trop Med Hyg 1955; 4(6): 970–9

    PubMed  CAS  Google Scholar 

  28. DuPont HL, Haynes GA, Pickering LK, et al. Diarrhea of travelers to Mexico: relative susceptibility of United States and Latin American students attending a Mexican university. Am J Epidemiol 1977; 105(1): 37–41

    PubMed  CAS  Google Scholar 

  29. Adachi JA, Ericsson CD, Jiang ZD, et al. Natural history of enteroaggregative and enterotoxigenic Escherichia coli infection among US travelers to Guadalajara, Mexico. J Infect Dis 2002; 185(11): 1681–3

    Article  PubMed  Google Scholar 

  30. Adachi JA, Jiang ZD, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler’s diarrhea in 3 regions of the world. Clin Infect Dis 2001; 32(12): 1706–9

    Article  PubMed  CAS  Google Scholar 

  31. Jiang ZD, Lowe B, Verenkar MP, et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 2002; 185(4): 497–502

    Article  PubMed  Google Scholar 

  32. Jiang ZD, Mathewson JJ, Ericsson CD, et al. Characterization of enterotoxigenic Escherichia coli strains in patients with travelers’ diarrhea acquired in Guadalajara, Mexico, 1992–1997. J Infect Dis 2000; 181(2): 779–82

    Article  PubMed  CAS  Google Scholar 

  33. Black RE. Epidemiology of travelers’ diarrhea and relative importance of various pathogens. Rev Infect Dis 1990; 12 Suppl. 1: S73–9

    Article  PubMed  Google Scholar 

  34. Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26(2): 341–5

    Article  PubMed  CAS  Google Scholar 

  35. Kuschner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995; 21(3): 536–41

    Article  PubMed  CAS  Google Scholar 

  36. DuPont HL, Ericsson CD, Mathewson JJ, et al. Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. JAMA 1992; 267(14): 1932–5

    Article  PubMed  CAS  Google Scholar 

  37. DuPont HL, Ericsson CD, Mathewson JJ, et al. Five versus three days of ofloxacin therapy for travelers’ diarrhea: a placebo-controlled study. Antimicrob Agents Chemother 1992; 36(1): 87–91

    Article  PubMed  CAS  Google Scholar 

  38. DuPont HL, Reves RR, Galindo E, et al. Treatment of travelers’ diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N Engl J Med 1982; 307(14): 841–4

    Article  PubMed  CAS  Google Scholar 

  39. Caeiro JP, Estrada-Garcia MT, Jiang ZD, et al. Improved detection of enterotoxigenic Escherichia coli among patients with travelers’ diarrhea, by use of the polymerase chain reaction technique. J Infect Dis 1999; 180(6): 2053–5

    Article  PubMed  CAS  Google Scholar 

  40. Ericsson CD, Patterson TF, DuPont HL. Clinical presentation as a guide to therapy for travelers’ diarrhea. Am J Med Sci 1987; 294(2): 91–6

    Article  PubMed  CAS  Google Scholar 

  41. Haberberger RL, Mikhail IA, Burans JP, et al. Travelers’ diarrhea among United States military personnel during joint American-Egyptian armed forces exercises in Cairo, Egypt. Mil Med 1991; 156(1): 27–30

    PubMed  Google Scholar 

  42. Mattila L. Clinical features and duration of travelers’ diarrhea in relation to its etiology. Clin Infect Dis 1994; 19(4): 728–34

    Article  PubMed  CAS  Google Scholar 

  43. Chapin AR, Carpenter CM, Dudley WC, et al. Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler’s diarrhea. J Clin Microbiol 2005; 43(3): 1112–7

    Article  PubMed  Google Scholar 

  44. von Sonnenburg F, Tornieporth N, Waiyaki P, et al. Risk and aetiology of diarrhoea at various tourist destinations. Lancet 2000; 356(9224): 133–4

    Article  Google Scholar 

  45. DuPont HL, Capsuto EG. Persistent diarrhea in travelers. Clin Infect Dis 1996; 22(1): 124–8

    Article  PubMed  CAS  Google Scholar 

  46. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997; 314(7083): 779–82

    Article  PubMed  CAS  Google Scholar 

  47. Okhuysen PC, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99(9): 1774–8

    Article  PubMed  Google Scholar 

  48. Taylor DN, Houston R, Shlim DR, et al. Etiology of diarrhea among travelers and foreign residents in Nepal. JAMA 1988; 260(9): 1245–8

    Article  PubMed  CAS  Google Scholar 

  49. Mintz ED, Weber JT, Guris D, et al. An outbreak of Brainerd diarrhea among travelers to the Galapagos Islands. J Infect Dis 1998; 177(4): 1041–5

    Article  PubMed  CAS  Google Scholar 

  50. Yanai-Kopelman D, Paz A, Rippel D, et al. Inflammatory bowel disease in returning travelers. J Travel Med 2000; 7(6): 333–5

    Article  PubMed  CAS  Google Scholar 

  51. Landzberg BR, Connor BA. Persistent diarrhea in the returning traveler: think beyond persistent infection. Scand J Gastroenterol 2005; 40(1): 112–4

    Article  PubMed  Google Scholar 

  52. Johnson PC, Ericsson CD, Morgan DR, et al. Lack of emergence of resistant fecal flora during successful prophylaxis of traveler’s diarrhea with norfloxacin. Antimicrob Agents Chemother 1986; 30(5): 671–4

    Article  PubMed  CAS  Google Scholar 

  53. Rademaker CM, Hoepelman IM, Wolfhagen MJ, et al. Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers’ diarrhea. Eur J Clin Microbiol Infect Dis 1989; 8(8): 690–4

    Article  PubMed  CAS  Google Scholar 

  54. Scott DA, Haberberger RL, Thornton SA, et al. Norfloxacin for the prophylaxis of travelers’ diarrhea in US military personnel. Am J Trop Med Hyg 1990; 42(2): 160–4

    PubMed  CAS  Google Scholar 

  55. Wistrom J, Norrby SR, Burman LG, et al. Norfloxacin versus placebo for prophylaxis against travellers’ diarrhoea. J Antimicrob Chemother 1987; 20(4): 563–74

    Article  PubMed  CAS  Google Scholar 

  56. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med 2005; 142(10): 805–12

    PubMed  CAS  Google Scholar 

  57. DuPont HL, Ericsson CD, Johnson PC, et al. Prevention of travelers’ diarrhea by the tablet formulation of bismuth sub-salicylate. JAMA 1987; 257(10): 1347–50

    Article  PubMed  CAS  Google Scholar 

  58. Dickens DL, DuPont HL, Johnson PC. Survival of bacterial enteropathogens in the ice of popular drinks. JAMA 1985; 253(21): 3141–3

    Article  PubMed  CAS  Google Scholar 

  59. Steffen R, Tornieporth N, Clemens SA, et al. Epidemiology of travelers’ diarrhea: details of a global survey. J Travel Med 2004; 11(4): 231–7

    Article  PubMed  Google Scholar 

  60. Sack DA, Kaminsky DC, Sack RB, et al. Prophylactic doxycycline for travelers’ diarrhea: results of a prospective double-blind study of Peace Corps volunteers in Kenya. N Engl J Med 1978; 298(14): 758–63

    Article  PubMed  CAS  Google Scholar 

  61. Sack RB, Froehlich JL, Zulich AW, et al. Prophylactic doxycycline for travelers’ diarrhea: results of a prospective double-blind study of Peace Corps volunteers in Morocco. Gastroenterology 1979; 76(6): 1368–73

    PubMed  CAS  Google Scholar 

  62. Sack RB, Santosham M, Froehlich JL, et al. Doxycycline prophylaxis of travelers’ diarrhea in Honduras, an area where resistance to doxycycline is common among enterotoxigenic Escherichia coli. Am J Trop Med Hyg 1984; 33(3): 460–6

    PubMed  CAS  Google Scholar 

  63. Gorbach S, Edelman R. Travelers. Rev Infect Dis 1986; 8 Suppl. 2: S109–233

    Article  Google Scholar 

  64. Farthing MJG, DuPont HL, Guandalini S, et al. Treatment and prevention of travellers’ diarrhoea. Gastroenterol Int 1992; 5(3): 162–75

    Google Scholar 

  65. Gomi H, Jiang ZD, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler’s diarrhea in four geographic regions. Antimicrob Agents Chemother 2001; 45(1): 212–6

    Article  PubMed  CAS  Google Scholar 

  66. Gorbach SL. How to hit the runs for fifty million travelers at risk. Ann Intern Med 2005; 142(10): 861–2

    PubMed  Google Scholar 

  67. Taylor D, McKenzie R, Durbin A, et al. Double-blind, placebo-controlled trial to evaluate the use of rifaximin (200mg TID) to prevent diarrhea in volunteers challenged with Shigella flexneri 2a (2457T) [poster no. 2079]. Meeting of the American Society of Tropical Medicine and Hygiene; 2004 Nov 7–11; Miami (FL)

  68. Ericsson CD, Evans DG, DuPont HL, et al. Bismuth subsalicylate inhibits activity of crude toxins of Escherichia coli and Vibrio cholerae. J Infect Dis 1977; 136(5): 693–6

    Article  PubMed  CAS  Google Scholar 

  69. Graham DY, Estes MK, Gentry LO. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. Gastroenterology 1983; 85(5): 1017–22

    PubMed  CAS  Google Scholar 

  70. DuPont HL, Sullivan P, Evans DG, et al. Prevention of traveler’s diarrhea (emporiatric enteritis): prophylactic administration of subsalicylate bismuth. JAMA 1980; 243(3): 237–41

    Article  PubMed  CAS  Google Scholar 

  71. de dios Pozo-Olano J, Warram JH, Gomez RG. Effect of a lactobacilli preparation on traveler. Gastroenterology 1978; 74 (5 Pt 1): 829–30

    Google Scholar 

  72. Hilton E, Kolakowski P, Singer C, et al. Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J Travel Med 1997; 4(1): 41–3

    Article  PubMed  Google Scholar 

  73. Oksanen PJ, Salminen S, Saxelin M, et al. Prevention of travellers’ diarrhoea by Lactobacillus GG. Ann Med 1990; 22(1): 53–6

    Article  PubMed  CAS  Google Scholar 

  74. DuPont HL, Olarte J, Evans DG, et al. Comparative susceptibility of Latin American and United States students to enteric pathogens. N Engl J Med 1976; 295(27): 1520–1

    Article  PubMed  CAS  Google Scholar 

  75. Gorbach SL, Kean BH, Evans DG, et al. Travelers’ diarrhea and toxigenic Escherichia coli. N Engl J Med 1975; 292(18): 933–6

    Article  PubMed  CAS  Google Scholar 

  76. Ericsson CD, DuPont HL, Sullivan P, et al. Bicozamycin, a poorly absorbable antibiotic, effectively treats travelers’ diarrhea. Ann Intern Med 1983; 98(1): 20–5

    PubMed  CAS  Google Scholar 

  77. Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003; 37(9): 1165–71

    Article  PubMed  CAS  Google Scholar 

  78. DuPont HL, Ericsson CD, Galindo E, et al. Furazolidone versus ampicillin in the treatment of traveler’s diarrhea. Antimicrob Agents Chemother 1984; 26(2): 160–3

    Article  PubMed  CAS  Google Scholar 

  79. DuPont HL, Ericsson CD, Mathewson JJ, et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea. Digestion 1998; 59(6): 708–14

    Article  PubMed  CAS  Google Scholar 

  80. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33(11): 1807–15

    Article  PubMed  CAS  Google Scholar 

  81. Ericsson CD, DuPont HL, Mathewson JJ. Optimal dosing of ofloxacin with loperamide in the treatment of non-dysenteric travelers’ diarrhea. J Travel Med 2001; 8(4): 207–9

    Article  PubMed  CAS  Google Scholar 

  82. Ericsson CD, DuPont HL, Mathewson JJ. Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of traveler’s diarrhea. J Travel Med 1997; 4(1): 3–7

    Article  PubMed  Google Scholar 

  83. Ericsson CD, Johnson PC, DuPont HL, et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers’ diarrhea: a placebo-controlled, randomized trial. Ann Intern Med 1987; 106(2): 216–20

    PubMed  CAS  Google Scholar 

  84. Petruccelli BP, Murphy GS, Sanchez JL, et al. Treatment of traveler’s diarrhea with ciprofloxacin and loperamide. J Infect Dis 1992; 165(3): 557–60

    Article  PubMed  CAS  Google Scholar 

  85. Salam I, Katelaris P, Leigh-Smith S, et al. Randomised trial of single-dose ciprofloxacin for travellers’ diarrhoea. Lancet 1994; 344(8936): 1537–9

    Article  PubMed  CAS  Google Scholar 

  86. Taylor DN, Sanchez JL, Candler W, et al. Treatment of travelers’ diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann Intern Med 1991; 114(9): 731–4

    CAS  Google Scholar 

  87. Wistrom J, Jertborn M, Hedstrom SA, et al. Short-term self-treatment of travellers’ diarrhoea with norfloxacin: a placebo-controlled study. J Antimicrob Chemother 1989; 23(6): 905–13

    Article  PubMed  CAS  Google Scholar 

  88. DuPont HL, Cooperstock M, Corrado ML, et al. Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 Suppl. 1: S228–35

    Article  PubMed  Google Scholar 

  89. Nachamkin I, Ung H, Li M. Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA, 1982–2001. Emerg Infect Dis 2002; 8(12): 1501–3

    Article  PubMed  Google Scholar 

  90. Saenz Y, Zarazaga M, Lantero M, et al. Antibiotic resistance in Campylobacter strains isolated from animals, foods, and humans in Spain in 1997–1998. Antimicrob Agents Chemother 2000; 44(2): 267–71

    Article  PubMed  CAS  Google Scholar 

  91. Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992–1998. Investigation Team. N Engl J Med 1999; 340(20): 1525–32

    CAS  Google Scholar 

  92. Murphy GS, Echeverria P, Jackson LR. Ciprofloxacin- and azithromycin-resistant Campylobacter causing traveler. Clin Infect Dis 1996; 22(5): 868–9

    Article  PubMed  Google Scholar 

  93. Krausse R, Ullmann U. In vitro activities of new fluoroquinolones against Campylobacter jejuni and Campylobacter coli isolates obtained from humans in 1980 to 1982 and 1997 to 2001. Antimicrob Agents Chemother 2003; 47: 2946–50

    Article  PubMed  CAS  Google Scholar 

  94. Ashley DV, Walters C, Dockery-Brown C, et al. Interventions to prevent and control food-borne diseases associated with a reduction in traveler’s diarrhea in tourists to Jamaica. J Travel Med 2004; 11(6): 364–7

    Article  PubMed  Google Scholar 

  95. Steffen R, Collard F, Tornieporth N, et al. Epidemiology, etiology, and impact of traveler’s diarrhea in Jamaica. JAMA 1999; 281(9): 811–7

    Article  PubMed  CAS  Google Scholar 

  96. Peltola H, Siitonen A, Kyronseppa H, et al. Prevention of travellers’ diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991; 338(8778): 1285–9

    Article  PubMed  CAS  Google Scholar 

  97. Guerena-Burgueno F, Hall ER, Taylor DN, et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 2002; 70(4): 1874–80

    Article  PubMed  CAS  Google Scholar 

  98. Freedman DJ, Tacket CO, Delehanty A, et al. Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli. J Infect Dis 1998; 177(3): 662–7

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The work was supported in part by grants from Public Health Service (grant DK 56338), which funds the Texas Gulf Coast Digestive Diseases Center. The author has consulted with, received honoraria for speaking and has received research grants administered through the University of Texas — Houston School of Public Health from Salix Pharmaceutical Company, Raleigh, NC, USA.

Author information

Authors and Affiliations

  1. University of Texas — Houston School of Public Health and Medical School, St. Luke’s Episcopal Hospital and Baylor College of Medicine, Houston, Texas, USA

    Herbert L. DuPont

Authors
  1. Herbert L. DuPont
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Herbert L. DuPont.

Rights and permissions

Reprints and permissions

About this article

Cite this article

DuPont, H.L. Travellers’ Diarrhoea: Contemporary Approaches to Therapy and Prevention. Drugs 66, 303–314 (2006). https://doi.org/10.2165/00003495-200666030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666030-00003

Keywords

Search

Navigation